CD4 and neoplasm: The authors speculated that other irrelevant antigens may be used similarly, and had previously shown that injecting the pan MHC class II-binding peptide (pan HLA-DR reactive epitope; PADRE) helped control tumours through the generation of CD4+ T helper cells [170].